The TAME trial, a phase III clinical trial, aimed to investigate whether targeted therapeutic mild hypercapnia (TTMH) could improve neurological outcomes at 6 months for resuscitated cardiac arrest patients in comparison to standard care (targeted normocapnia). This study holds significant importance in exploring potential advancements in post-cardiac arrest treatment strategies.

The world of REMAP-CAP is constantly evolving, here’s what’s new!

REMAP-CAP, a groundbreaking trial that has most recently been primarily focused on finding treatments for COVID-19, has now been selected by the National Institute for Healthcare and Research to evaluate therapeutic interventions for influenza.

New results have recently been published from the ACE2 RAS domain, one of the multiple therapeutic domains within REMAP-CAP, a trial within Spiral’s manifest of studies.

We have another important milestone to celebrate! On the 17th of February 2023, the SNAP (Staphylococcus Aureus Network Adaptive Platform) Trial reached its one-year anniversary.

Spiral talks with Ly-Mee Yu, Lead Statistician of the PANORAMIC Trial on the devastating effects of the pandemic and how trials like PANORAMIC, with the help of Spiral’s software, are aiming to provide better health outcomes for those affected by the virus.

As clinical trials in the world grow and develop, so too do the opportunities for Spiral to make a difference with our savvy platform software. 

We speak to Professor Steven Tong about the SNAP Trial, his experience working with the team at Spiral, and the application and impact of our Spinnaker software in his study.

At Spiral, we’re always working hard to better meet the needs of our clients and partners. As our product evolves so too does our team. Meet Anna Williams, the newest full-time member of the Spiral whānau (family). Our office manager and data coordinator.  

Meet Mel, the newest project manager to join our Spiral team. Mel has only been with us a few weeks but has settled into her role marvellously, bringing with her a background in project and account management as well as her recently acquired skills and knowledge in development.

Over ten thousand participants from right across the UK have now taken part in the NIHR-funded and supported PANORAMIC trial - the world’s largest study into new antiviral treatments against COVID-19 in community, ambulatory care.

REMAP-CAP, the Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia, has recently hit a significant date in its trial history, celebrating two years since the first Covid-19 ICU patient was randomised into the trial.